Press Releases

Archives: Search / 2019

201820172016201520142013201220112010200920082007

Sep 13, 2019
Discontinuation of studies based on Data Safety Monitoring Board recommendation

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...

More
Aug 26, 2019

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Priya Chaturvedi, Ph.D., as Vice President, Global Clinical Quality Assurance. Dr....

More
Jul 23, 2019
Designation Granted for Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment

Kenilworth, N.J., and Woodcliff Lake, N.J., July 23, 2019 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug...

More
Jul 11, 2019

In the news release, New Data in 2 Oral and 13 Poster Presentations about Eisai's Latest Dementia Pipeline, Including BAN2401, Elenbecestat and Lemborexant, to be Presented at Alzheimer's...

More
Jul 9, 2019
New Research Center Focused on Immunotherapy for Dementia

Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd., announced today the opening of its Eisai Center for Genetics Guided Dementia Discovery ("G2D2"), a new exploratory research facility located in...

More
Jun 25, 2019
- Results of the FREEDOM Study (Study 342) presented at the 33rd International Epilepsy Congress (IEC)

Eisai Inc. today announced results from its FREEDOM Study (Study 342), a Phase III open-label study conducted in Japan and South Korea evaluating the efficacy and safety of FYCOMPA® (perampanel)...

More
Jun 13, 2019
-Results from the FREEDOM study, evaluating seizure freedom rates of FYCOMPA in new onset patients, including analyses at the 4 mg/day dose

Eisai Inc. today announced that it will present new data for FYCOMPA® (perampanel) CIII, including FREEDOM study results and the final results of one of the pediatric studies that supported the...

More
Jun 11, 2019
New Phase 1 study on investigational treatment explores safety of lemborexant in healthy adult and elderly populations, and those with mild obstructive sleep apnea

Eisai Inc. today announced data on the respiratory safety of investigational lemborexant with multiple and single dosing in healthy adult and elderly individuals, as well as in those with mild...

More
Jun 11, 2019
New analyses presented at SLEEP 2019 evaluated impact on key insomnia measures, including disease severity, sleep onset, sleep maintenance, and long-term safety, as well as next-day functioning

Eisai Inc. today announced new long-term safety and pooled analyses from the Phase 3 clinical development program for lemborexant, an investigational agent for sleep-wake regulation, currently...

More
Jun 4, 2019
- Targeting CXCR4 May Impact Aggressive Metastatic Behavior of Cancer Cells, Which May be Related to a Poor Prognosis

Eisai today announced additional data from an ongoing Phase 1 trial exploring the investigational combination of eribulin and balixafortide, a CXCR4 antagonist, in patients with HER2-negative...

More
Jun 4, 2019

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Patrick Coyle as Vice President and Chief Financial Officer (CFO). In this role, Mr....

More
May 29, 2019

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Adriana Herrera as Senior Vice President, Americas Commercial Oncology. Herrera will...

More
May 28, 2019
Data to be presented include:

Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") today announced eight poster presentations on lemborexant, an investigational agent being studied for the treatment of insomnia, a sleep-wake disorder,...

More
May 20, 2019

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Dr. Luca Dezzani as Vice President, U.S. Medical Affairs, Oncology Business Group....

More
May 16, 2019
- Data highlight continued progress on clinical trials for the LENVIMA plus KEYTRUDA combination across multiple tumor types, including endometrial carcinoma (EC), for which the combination was granted U.S. FDA Breakthrough Therapy Designation in July 2018

Eisai today announced the presentation of new data and analyses in one oral presentation, 11 posters at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4 in...

More
May 13, 2019

The Alzheimer's Clinical Trials Consortium (ACTC) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the investigational oral BACE (beta amyloid cleaving...

More
May 9, 2019
-- Eisai presents key data from three retrospective real-world analyses at the 2019 American Academy of Neurology (AAN) Annual Meeting

Eisai Inc. presented the latest clinical results on FYCOMPA® (perampanel) CIII, at the 2019 American Academy of Neurology Annual Meeting in Philadelphia, including analyses highlighting the...

More
May 2, 2019
Dr. Harald Hampel hired as Vice President, Global Medical Affairs, Alzheimer's Disease;

In its relentless pursuit to develop medications that will address the entire scope of Alzheimer's disease (AD), Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced...

More
Apr 30, 2019

Eisai Inc. and Purdue Pharma L.P. today announced that Eisai will buy out Purdue's rights to the worldwide collaboration for the development and commercialization of lemborexant, an...

More
Apr 24, 2019
Presentations include:

Eisai Inc. today announced that one oral presentation and 20 poster presentations from its neurology portfolio will be featured at the American Academy of Neurology's (AAN) Annual Meeting, May...

More